Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?
Are there certain mutations that would lead you to avoid use of lenalidomide, for example TP53?
Related Questions
Would you still recommend bone marrow biopsy in an elderly non-transplant eligible patient with mild cytopenias if NGS from peripheral blood indicates MDS mutations?
Is there an advantage to early therapy with hypomethylating agents for high/very high risk patients with MDS who are not transplant candidates and have only mild cytopenias?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
How do you monitor multiple myeloma in patients receiving dialysis?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?